Orphan drugs – multilingual communication involving rare diseases

The target group for these medications is very small and clearly defined. By definition, “rare diseases” affect less than five out of 10,000 people. However, on a global scale, about 300 million people are affected by them—about 4 million in Germany alone. While that may sound manageable, the facts tell a different story.

They live in Warsaw and Rome, in Vienna and Helsinki. Despite sharing similar needs, they are fragmented by linguistic barriers, distinct healthcare infrastructures, and separate patient support groups. Their doctors communicate in technical jargon that varies considerably, even within Europe.

For pharmaceutical or healthcare companies seeking to bring an orphan drug (medication for rare diseases, known as orphan diseases) to market, multilingual communication is therefore a core business strategy, not just a localized translation task. It is a critical make-or-break variable for regulatory approval, patient safety, and market penetration.

Small populations, uncompromising precision

In the European Union, approximately 250,000 people are affected by a rare disease – across 27 member states with 24 official languages. For many medications, this means that there are only a few hundred, or maybe even only a few dozen, patients per target market.

Conventional translation logistics based on high volume, standardized processes, and economies of scale through translation memories fall short in this context. While the text volumes are small, the demand for terminological precision is exceptionally high. Inconsistent translations of a single term in a multinational clinical trial can compromise the statistical validity and comparability of clinical data. It may even trigger regulatory inquiries.

To make matters worse, nomenclature for rare diseases often lacks strict standardization, leading to terminological inconsistencies even among medical professionals. For some genetic syndromes, there are still no established translations in certain languages. This means that translators must not only possess advanced linguistic proficiency but also comprehensive subject-matter expertise in the medical and scientific fields. For best results, they must also work closely with the company’s medical teams to build terminology databases from the very beginning.

PSP – quality care leaves no margin for error

Patient Support Programs (or PSPs for short) are structured support programs that assist patients beyond simply providing medication. They also provide informational materials, training for caregivers, hotlines, digital platforms, and home visits by specialized professionals. For orphan drugs, PSPs bridge the gap between treatment availability and actual patient access. Many of these patients have lived for years without a diagnosis, often reside in medically underserved regions, and are frequently the first in their communities to undergo a specific treatment.

Simultaneously rolling out PSPs across multiple countries can be a logistical nightmare due to complex coordination patterns. Beyond the obvious language barriers, patient communication requires navigating entirely different regulatory frameworks. For example, patient information authorized in Germany may fall under France’s strict advertising ban on prescription drugs. Consequently, besides simply translating information material, it must also be adapted to each country’s specific requirements and reviewed for legal compliance.

Errors in PSP materials, including incorrectly translated dosage instructions, unclear descriptions of side effects, or culturally inappropriate phrasing, have direct consequences for patient safety. While it is common knowledge that “the food industry does not forgive mistakes,” pharmaceutical communication is even less forgiving.

RWE studies – when translation errors compromise data integrity

For conventional drugs, approval is primarily based on randomized controlled trials, the gold standard of clinical research. With orphan drugs, the same approach is often not possible, because the patient populations are too small to form statistically valid control groups. To overcome this constraint, regulators such as the European Medicines Agency (EMA) are therefore increasingly accepting real-world evidence (RWE) studies. These analyses use data derived from routine clinical practice, including medical records, patient registries, and healthcare data.

By definition, these studies are multilingual. Patient data from a German university hospital, a French specialty center, and a Spanish patient organization must be consolidated, harmonized, and documented in a single common language—usually English. This introduces translation risks at multiple levels simultaneously, including medical terminology, statistical jargon, country-specific coding systems, and regulatory reporting formats.

A translation error in a real-world evidence (RWE) study is not merely an editorial issue. It can compromise data integrity and trigger regulatory inquiries. In worst-case scenarios, it may even delay approval. This has direct repercussions for patients awaiting treatment.

Case study: A biotech startup launches orphan drugs in the EU5 markets

The specific scenario: An Austrian biotech startup has developed a gene therapy for a rare lysosomal storage disorder and has received conditional marketing authorization from the European Medicines Agency (EMA). The initial rollout is planned for the EU5 markets (Germany, France, Italy, Poland, Spain) as well as the United Kingdom (despite Brexit) via a separate MHRA approval.

The company has twelve employees. Unfortunately, it does not have an in-house translation team or a localized regulatory affairs team in the target markets.

• Immediate requirements: Product information (Summary of Product Characteristics and patient information leaflet) in five languages, adapted to each country and compliant with regulatory requirements. Additional requirements: Info materials for physicians, training materials for PSP coordinators, a website for patients and their families, and communication materials for patient organizations—all within a tight schedule, because the conditional approval is subject to requirements that must be met within defined deadlines.
• The main problem: The Summary of Product Characteristics (SmPC) was first translated in-house into English and then delegated to five different freelancers—one per language. The result: five versions with five different sets of terminology. There are three distinct translations for the disease name itself. The French version contains wording that could be classified as unauthorized advertising under French pharmaceutical law. The Spanish version uses a dosage specification in the wrong format.
• Better solution: Centralized terminology management from the start, a coordinated translation process with a single point of contact for all five markets, country-specific legal expertise as an integral part of the translation workflow, and no post-translation review step.

Rare diseases and cultural sensitivities – sometimes a diagnosis is more than a medical finding

A genetic disorder diagnosis is never just a medical issue. It carries deep personal weight, bringing up questions of family history, inherited guilt, religious beliefs, and social stigmas. The intensity of this emotional experience varies considerably from culture to culture.

In some Southern European and Middle Eastern cultures, the idea of having “passed on” a genetic disorder is associated with deep feelings of shame and guilt. Other cultures believe that illnesses and their outcomes are entirely predetermined by fate, which complicates active treatment management. Still other communities, such as populations that are disproportionately affected by certain hereditary diseases, have developed their own communication cultures surrounding genetic disorders over generations.

What does this mean for translation? It means that a word-for-word approach is not sufficient here. An information sheet that sounds factual and empowering in German may be perceived as cold, stigmatizing, or even threatening in Arabic or Turkish if it is translated literally and not adapted culturally.

Patient communication regarding genetic disorders therefore requires translators who are not only proficient in the target language but also understand how cultural backgrounds define a person’s relationship to sickness, family, and guilt.

This requires careful consideration and cannot be taken lightly. It can be the deciding factor in a patient’s willingness to continue treatment.

Regulatory nuances – jurisdictional variations in accelerated approval

Orphan drugs benefit from accelerated approval processes in many jurisdictions. However, these processes vary by region.

• The EMA’s Conditional Marketing Authorization (CMA) is granted based on preliminary data if the benefits outweigh the risks and the applicant commits to submitting additional study data.
• In the U.S., the FDA’s Accelerated Approval Pathway is based on surrogate endpoints, which are measurable biomarkers that are accepted as proxies for clinical endpoints.
• After Brexit, Great Britain developed its own approach with the MHRA’s Innovative Licensing and Access Pathway (ILAP).
• Japan, Canada, and Australia also have their own mechanisms.

Therefore, regulatory document submissions require region-specific localization rather than straightforward translation. Regulatory terminology is not directly transferable. Terms like “Conditional Marketing Authorization” and “Accelerated Approval” describe similar but not identical concepts, with different legal implications.

Anyone who incorrectly translates or misinterprets these terms in patient information leaflets or press releases risks drawing regulatory scrutiny and spreading misinformation among patients and physicians.

This issue is further complicated by differing requirements for package inserts, Summary of Product Characteristics, and risk management plans. These documents must be available in the local language and approved by regulatory authorities in each jurisdiction. Needless to say, translation is part of the approval process in this context.

Patient advocacy groups – connecting as equals in the language that feels right

Patient advocacy groups are patient organizations that actively champion the interests of a specific patient population. When it comes to providing care for people with rare diseases, they act as strategic partners, extending far beyond traditional advocacy. They are often the primary source of information for newly diagnosed patients. They coordinate patient registries and influence reimbursement decisions. Often, they are the only stakeholders who can reach scattered patient populations at all.

For biotech companies, these groups are therefore not a target audience in the traditional marketing sense. They are strategic partners. Communication with advocacy groups thrives on genuine collaboration and mutual respect. It delivers clear, precise, and practical insights tailored directly to the community’s unique situation without marketing jargon, and in the respective language.

It sounds straightforward on paper, but the execution is far more complex: An English press release that is machine-translated into French and sent to a French patient advocacy group without being proofread shows a blatant disregard for the intended audience, regardless of the message. Advocacy groups that have fought for years for the recognition of a rare disease are sensitive to such a lack of professional courtesy. And it leaves a lasting impression.

Multilingual communication as a strategic infrastructure for healthcare

In the field of orphan drugs, multilingual communication is not a downstream service that is simply purchased at the end of the development process. It is a strategic infrastructure service that must be factored in from the very beginning.

The criteria are stringent: medical and scientific expertise, regulatory knowledge across multiple jurisdictions, cultural sensitivity, and a coordinated process that ensures terminological consistency across all markets and documents. This is not a task for a network of uncoordinated freelancers. It is a task for a language service provider that views medical translations not as a simple administrative task, but as a critical component of patient safety and regulatory compliance.